On-demand transarterial chemoembolisation combined with atezolizumab and bevacizumab in patients with untreated hepatocellular carcinoma (TALENTACE): a multicentre, randomised, open-label, phase 3 trial
Study limitation reported by the research below: “The brand name 'Tecentriq' is used for atezolizumab; availability and labelling may vary by region.”